Skip to main content
. 2021 Mar 18;11:6328. doi: 10.1038/s41598-021-85948-2

Figure 1.

Figure 1

Time to treatment failure according to baseline levels of (A) ALC, (B) NLR, (C) PLR, and (D) LMR in patients treated with paclitaxel plus bevacizumab. ALC absolute lymphocyte count, CI confidence interval, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.